

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 6-K**

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934

For the month of January, 2026

Commission File Number: **001-42128**

**Telix Pharmaceuticals Limited**

(Translation of registrant's name into English)

**55 Flemington Road**  
**North Melbourne, Victoria 3051, Australia**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

---

**INFORMATION CONTAINED IN THIS FORM 6-K REPORT**

On January 20, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited (the “Company”) filed an announcement with the Australian Securities Exchange (“ASX”) titled “Chinese NMPA Accepts New Drug Application for Illucix,” which is attached to this Form 6-K as Exhibit 99.1 (“First ASX Release”).

On January 20, 2026 (Melbourne, Australia), the Company filed an announcement with the ASX titled “Telix Achieves FY 2025 Guidance with US\$804M (AS1.2B) Revenue, Accelerates Growth with Gozellix Launch,” which is attached to this Form 6-K as Exhibit 99.2 (“Second ASX Release”).

[99.1](#)  
[99.2](#)

First ASX Release

Second ASX Release

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Telix Pharmaceuticals Limited**

Date: January 20, 2026

By:           /s/ Genevieve Ryan            
Name: Genevieve Ryan  
Title: Company Secretary

---

**Telix Achieves FY 2025 Guidance with US\$804M (A\$1.2B) Revenue,  
Accelerates Growth with Gozellix Launch**

Melbourne (Australia) and Indianapolis, IN (U.S.) – 20 January 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4 2025).

**Q4 2025 Highlights**

- Full-year (FY) 2025 unaudited Group revenue of approximately US\$804 million (A\$1.2 billion<sup>1</sup>), in line with upgraded guidance of US\$800-\$820 million<sup>2</sup> (previously US\$770-800 million).
- Q4 2025 unaudited Group revenue of approximately US\$208 million, up 46% year-over-year.
- Precision Medicine business revenue of approximately US\$161 million, up 4% quarter-over-quarter, driven by the successful United States (U.S.) launch of Gozellix® following reimbursement by Centers for Medicare and Medicaid Services (CMS), effective from 1 October 2025<sup>3</sup>.
- First international patients treated in Part 2 (randomized expansion) of the ProstACT® Global Phase 3 study of TLX591-Tx in advanced prostate cancer<sup>4</sup>.
- First U.S. patients treated in the SOLACE Phase 1 study of TLX090-Tx in patients with pain from bone metastases<sup>5</sup>.
- Announced strategic collaboration with Varian, a Siemens Healthineers company, to explore the combination of Telix’s radiopharmaceuticals with external beam radiation therapy (EBRT)<sup>6</sup>.

**Q4 2025 Revenue (Unaudited)**

Revenue (US\$M)	Q4 2025	Q4 2024	Variation	Q3 2025	Variation
Group revenue	208	142	46%	206	1%
Precision Medicine revenue <sup>7</sup>	161	139	16%	155	4%
RLS third-party revenue <sup>8</sup>	45	—	—	47	(4)%

<sup>1</sup> Converted at the full year 2025 average US\$:A\$ exchange rate of 1.55:1

<sup>2</sup> Telix ASX disclosure 14 October 2025.

<sup>3</sup> Telix ASX disclosure 23 September 2025.

<sup>4</sup> Telix media release 8 December 2025. ClinicalTrials.gov ID: [NCT06520345](https://clinicaltrials.gov/ct2/show/study/NCT06520345).

<sup>5</sup> Telix media release 23 October 2025. ClinicalTrials.gov ID: [NCT07197645](https://clinicaltrials.gov/ct2/show/study/NCT07197645).

<sup>6</sup> Telix media release 10 December 2025.

<sup>7</sup> Primarily sales of Illuccix and Gozellix in our Precision Medicine business.

<sup>8</sup> RLS Radiopharmacies revenue excludes revenue contribution from Illuccix and Gozellix sales.

---

## Commentary and business highlights

Dr. Christian Behrenbruch, Managing Director and Group CEO, stated, “Telix’s Precision Medicine business delivered excellent sequential growth in Q4 2025, driven in part by the successful U.S. launch of Gozellix. This revenue growth outpaced a 3% increase in dose volumes, demonstrating the positive impact of our two-product strategy on market share and pricing. With strong early uptake of Gozellix and a robust pipeline of key accounts integrating Gozellix and ARTMS technology, Telix is well positioned for sustained growth in 2026.”

## Therapeutics business

- **TLX591-Tx (lutetium (<sup>177</sup>Lu) rosopatamab tetraxetan):** Telix is preparing for a readout of safety and dosimetry data from Part 1 of ProstACT Global, the Phase 3 trial of its lead prostate cancer therapy candidate. Part 2 (randomized treatment expansion) has commenced following data safety review and dosed first patients. The study is open for enrollment in Australia, New Zealand and Canada, with further sites to be opened in China, Singapore, South Korea, Türkiye, the United Kingdom and Japan<sup>9</sup>, where regulatory approvals have already been granted. Data from Part 1 will be presented to the U.S. Food and Drug Administration (FDA) to ascertain eligibility for U.S. patients to participate in Part 2.
- **TLX592-Tx (<sup>225</sup>Ac-PSMA-RADmAb):** Telix is preparing to activate sites for AlphaPRO, a first-in-human (FIH) study of its targeted alpha therapy candidate for prostate cancer. The study will initially recruit ex-U.S.
- **TLX250-Tx (<sup>177</sup>Lu-DOTA-girentuximab):** Telix is commencing site activations ahead of opening patient enrollment in LUTEON<sup>10</sup>, its pivotal trial of TLX250-Tx as a monotherapy in metastatic clear cell renal cell carcinoma (ccRCC). The study will initially recruit ex-U.S.
- **TLX252-Tx (<sup>225</sup>Ac-DOTA-girentuximab):** Telix has received approval in Australia to commence ALPHIX, a Phase 1, FIH study of its targeted alpha therapy candidate for advanced metastatic kidney cancer and other cancers that express carbonic anhydrase IX (CAIX).
- **TLX101-Tx (<sup>131</sup>I-iodofalan):** Telix is enrolling patients at Australian sites in IPAX-BRIGHT, an international pivotal trial of TLX101-Tx in patients with recurrent glioblastoma<sup>11</sup>. European sites are expected to join the study in Q1 2026.
- **TLX102-Tx (<sup>211</sup>At astato-L-phenylalanine):** Telix is preparing to commence a FIH study of TLX102-Tx, its alpha therapy candidate targeting L-type amino acid transporter 1 (LAT1), in patients with leptomeningeal disease (LMD). The FDA has acknowledged LMD as a significant unmet medical need and provided positive written feedback on a two-part study design (dose escalation and safety expansion), along with guidance on a combined protocol for imaging and therapy to enable a true theranostic evaluation, including potential future label expansion for TLX101-Px.
- **TLX090-Tx (<sup>153</sup>Sm-DOTMP):** Telix has dosed the first U.S. patients in SOLACE<sup>12</sup>, a Phase 1 study of its therapeutic candidate for treating pain in patients with osteoblastic bone metastases from prostate and breast cancers.

---

<sup>9</sup> Japanese regulator Pharmaceuticals and Medical Devices Agency (PMDA) has granted approval for a Japan-specific Part 1 in nine patients, prior to commencing Part 2.

<sup>10</sup> ClinicalTrials.gov ID: [NCT07197580](https://clinicaltrials.gov/ct2/show/study/NCT07197580).

<sup>11</sup> ClinicalTrials.gov ID: [NCT07100730](https://clinicaltrials.gov/ct2/show/study/NCT07100730).

<sup>12</sup> Telix media release 23 October 2025.

---

## Precision Medicine business

### **PSMA portfolio (Illuccix and Gozellix):**

- Following approval of Illuccix® in Spain<sup>13</sup>, Telix now holds marketing authorizations for all 19 European countries that were included in its decentralized procedure (DCP) submission. Commercial launches have commenced in 12 European countries including France, Germany, Spain and the United Kingdom as reimbursement is secured on a market-by-market basis.
- Australian hospitals and imaging centers continue to effectively transition from in-house production of <sup>68</sup>Ga-PSMA-11 to Illuccix®, with Telix's approved agent now the leading PSMA-PET<sup>14</sup> tracer nationally (approximately 55% market share at 31 December 2025)<sup>15</sup>.
- The Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the New Drug Application (NDA) filing for TLX591-Px (Illuccix)<sup>16</sup>. This follows positive top-line results from the Illuccix China Pivotal Phase 3 registration study<sup>17</sup>, which reported an overall patient-level positive predictive value (PPV) of 94.8% for detecting tumors in patients with biochemical recurrence (BCR) of prostate cancer<sup>18</sup>.
- Telix has dosed the first U.S. patients in its BiPASS™ Phase 3 study<sup>19</sup> to evaluate magnetic resonance imaging (MRI) combined with its commercial PSMA-PET imaging agents, Illuccix and Gozellix, in the initial prostate cancer diagnosis setting. The trial is recruiting in Australia and the U.S.
- Telix has dosed the first patient in its Phase 3 registration study of TLX591-Px in Japan<sup>20</sup>. The study will enroll up to 105 Japanese men at 11 sites with data intended to support a future marketing authorization application for Illuccix in Japan.

### **Pixclara®<sup>21</sup> (TLX101-Px, Floretyrosine F18):**

- Telix has engaged in collaborative discussions with the FDA on additional clinical data and a revised statistical analysis plan, following a productive Type A meeting to review the basis of the Complete Response Letter (CRL). Telix is finalizing its resubmission package and will provide an update upon acceptance of the refiling.
- The approved Expanded Access Program (EAP) for TLX101-Px remains active, reflective of Telix's commitment to patients<sup>22</sup>.

### **Zircaix®<sup>23</sup> (TLX250-Px, <sup>89</sup>Zr-DFO-girentuximab):**

- In December 2025, Telix participated in a Type A meeting to discuss chemistry, manufacturing, and controls (CMC) deficiencies identified in the CRL for its Biologics License Application (BLA) for this ccRCC PET imaging candidate<sup>23</sup>. In January 2026, Telix participated in an additional Type A meeting to address clinical comparability between the drug product used in the ZIRCON Phase 3 clinical trial<sup>24</sup> and the product from scaled-up manufacturing intended for

---

<sup>13</sup> Telix media release 29 August 2025.

<sup>14</sup> Imaging of prostate-specific membrane antigen.

<sup>15</sup> Management estimate based on Medicare Benefit Schedule statistics, available at:

[medicarestatistics.humanservices.gov.au/](https://medicarestatistics.humanservices.gov.au/)

<sup>16</sup> Telix ASX disclosure 20 January 2026.

<sup>17</sup> ClinicalTrials.gov ID: [NCT05847348](https://clinicaltrials.gov/ct2/show/study/NCT05847348)

<sup>18</sup> Telix ASX disclosure 22 December 2025, Telix data on file. Illuccix China Clinical Study Report, December 2025.

<sup>19</sup> Biopsy of the Prostate Avoidance Stratification Study; ClinicalTrials.gov ID: [NCT07052214](https://clinicaltrials.gov/ct2/show/study/NCT07052214). Telix media release 16 January 2026.

<sup>20</sup> Japan Registry of Clinical Trials identifier: JRCT2031250473

<sup>21</sup> Brand name subject to final regulatory approval.

<sup>22</sup> ClinicalTrials.gov ID: [NCT06743100](https://clinicaltrials.gov/ct2/show/study/NCT06743100).

<sup>23</sup> Telix ASX disclosure 22 December 2025.

<sup>24</sup> ClinicalTrials.gov ID: [NCT03849118](https://clinicaltrials.gov/ct2/show/study/NCT03849118).

---

commercial use. Following this meeting, Telix believes it has alignment with the Agency on all key resubmission aspects. Telix will provide a further update on receipt of official FDA minutes from both meetings.

- TLX250-Px is now included in updated international guidelines from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Nuclear Medicine (EANM) and The American College of Nuclear Medicine (ACNM) for molecular imaging of renal masses, reflecting a shift toward precision medicine in renal cancer<sup>25</sup>.
- Data from ZIRCON-X, a non-interventional, prospective, study – using imaging data from Telix’s pivotal Phase 3 ZIRCON study – were presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO). The study evaluated the impact of TLX250-Px imaging on clinical decision-making versus standard contrast-enhanced imaging in 294 patients with indeterminate renal masses (IRMs). Outcomes demonstrated that 48.6% of patients (143) would have experienced a change in management if imaged with TLX250-Px, with over 20% of these (31 patients) potentially avoiding invasive biopsy<sup>26</sup>.
- The approved EAP for TLX250-Px remains active, reflective of Telix’s commitment to patients<sup>27</sup>.

### **Telix Manufacturing Solutions (TMS)**

In line with its stated strategy to invest in supply chain and production capabilities to meet future demand for radiopharmaceuticals, Telix is progressing several key projects:

- Upgrades to select RLS Radiopharmacies network sites for cyclotron installations to enable in-house production of critical therapeutic and diagnostic isotopes, along with enhanced manufacturing capabilities.
- A major upgrade of Good Manufacturing Practice (GMP) production facilities and clean rooms at the Angleton, Texas site for IsoTherapeutics, a Telix Company.
- Opening of a TMS site in Yokohama, Japan<sup>28</sup>. This is Telix's first cyclotron facility in the Asia Pacific region to support future product launch in Japan and regional clinical trials.
- Construction of a TMS-led translational research hub in North Melbourne, Australia, is in completion. The facility incorporates radiochemistry hot labs for clinical dose production and a patient dosing and imaging suite, including in-house SPECT/CT<sup>29</sup>.

These investments support vertical integration, supply chain control, and global centers of excellence for advancing Telix’s next-generation therapeutic radiopharmaceutical portfolio.

### **Corporate updates**

#### ***Strategic clinical collaboration with Varian***

Telix announced a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology. The collaboration focuses on developing novel clinical applications that combine Telix's theranostic products with EBRT, starting with PSMA-PET imaging for prostate cancer. This framework supports future co-development opportunities, including with

---

<sup>25</sup> Rowe et al. *J Nucl Med*. 2025. Telix media release 23 October 2025.

<sup>26</sup> Telix ZIRCON-X SUO 2025 abstract, available at: <https://suo-abstracts.secure-platform.com/a/gallery/rounds/24/details/4869>

<sup>27</sup> ClinicalTrials.gov ID: [NCT06090331](https://clinicaltrials.gov/ct2/show/study/NCT06090331).

<sup>28</sup> Telix media release 21 November 2025.

<sup>29</sup> Single-photon emission computed tomography combined with computed tomography.

---

other PET imaging candidates in Telix's pipeline (TLX250-Px and TLX101-Px) and potential future therapeutic radiopharmaceuticals.

### **About Telix Pharmaceuticals Limited**

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix has been approved by the FDA<sup>30</sup>, and in multiple markets globally. Gozellix has been approved by the FDA<sup>31</sup>. No other Telix product mentioned in this announcement has received a marketing authorization in any jurisdiction.

Visit [www.telixpharma.com](http://www.telixpharma.com) for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on [LinkedIn](#), [X](#) and [Facebook](#).

### **Telix Investor Relations (Global)**

Ms. Kyahn Williamson  
Telix Pharmaceuticals Limited  
SVP Investor Relations and Corporate Communications  
Email: [kyahn.williamson@telixpharma.com](mailto:kyahn.williamson@telixpharma.com)

### **Telix Investor Relations (U.S.)**

Annie Kasparian  
Telix Pharmaceuticals Limited  
Director Investor Relations and Corporate Communications  
Email: [annie.kasparian@telixpharma.com](mailto:annie.kasparian@telixpharma.com)

*This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors.*

### Legal Notices

#### *Cautionary Statement Regarding Forward-Looking Statements.*

*You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.*

*The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.*

---

<sup>30</sup> Telix ASX disclosure 20 December 2021.

<sup>31</sup> Telix ASX disclosure 21 March 2025.

---

*This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.*

*Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the © or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.*

©2026 Telix Pharmaceuticals Limited. All rights reserved.

### **Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging**

Melbourne (Australia) and Indianapolis, IN (U.S.) – 20 January 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the filing of a New Drug Application (NDA) for TLX591-Px (Illuccix®, Kit for the preparation of <sup>68</sup>Ga-PSMA-11), Telix’s lead prostate cancer imaging agent.

The NDA was submitted with Telix’s strategic partner for the Greater China region, Grand Pharmaceutical Group Limited (00512.HK, Grand Pharma). Seeking a broad label that reflects clinical utility at multiple stages of prostate cancer care, the submission includes data from the Illuccix China Pivotal Phase 3 Registration study<sup>1</sup>, which reported positive top-line results in December 2025<sup>2</sup>.

The Illuccix China study met its primary endpoint, with an overall patient-level positive predictive value (PPV) of 94.8% for the detection of tumors in patients with biochemical recurrence (BCR) of prostate cancer with TLX591-Px<sup>2,3</sup>. This confirmed that the clinical experience of TLX591-Px PSMA-PET<sup>4</sup> imaging in Chinese patients is comparable to studies in non-Chinese patients. The high PPV was demonstrated even in patients with very low PSA<sup>5</sup> values, and across differing metastatic locations. More than two-thirds (67.2%) of patients experienced a change in their treatment plan as a consequence of TLX591-Px PSMA-PET imaging compared with the initial plan at baseline<sup>3</sup>, demonstrating a major impact on clinical decision-making in Chinese patients.

Kevin Richardson, Chief Executive Officer, Precision Medicine, Telix, commented, “Submitting this New Drug Application for TLX591-Px, the first for any of our products in China, is a major milestone for Telix and our partner Grand Pharma. Geographic expansion is core to the growth strategy for our precision medicine business, and China represents a strategically important market for Telix. We look forward to progressing regulatory approvals together with Grand Pharma and subject to NMPA approval, bringing our lead commercial imaging product to market in China to serve the needs of men living with prostate cancer.”

#### **About Prostate Cancer in China**

In China, more than 134,000 men were diagnosed with prostate cancer in 2022<sup>6</sup>, increasing by approximately 6% each year<sup>7</sup>. In line with government policy supporting wider geographic access to nuclear medicine, the number of PET/CT cameras installed in China is expected to have surpassed 1,600 at the end of 2025<sup>8</sup>, compared with 133 in 2010<sup>9</sup>.

<sup>1</sup> ClinicalTrials.gov ID: NCT05847348.

<sup>2</sup> Telix ASX disclosure 22 December 2025.

<sup>3</sup> Telix data on file. Illuccix China Clinical Study Report, December 2025.

<sup>4</sup> Imaging of prostate-specific membrane antigen with positron emission tomography.

<sup>5</sup> Prostate-specific antigen.

<sup>6</sup> Global Cancer Statistics 2022: GLOBOCAN survey. Published August 2024.

<sup>7</sup> Ye Dingwei et al. *Lancet Oncology*, 2022.

<sup>8</sup> Yang et al. *J Nuc. Med.* 2024.

## About Illuccix

Telix's lead prostate imaging product, gallium-68 (<sup>68</sup>Ga) gozetotide injection (also known as <sup>68</sup>Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)<sup>10</sup>, by the Australian Therapeutic Goods Administration (TGA)<sup>11</sup>, by Health Canada<sup>12</sup>, by the Brazilian Health Regulatory Agency (ANVISA)<sup>13</sup>, by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA)<sup>14</sup> and in 19 countries within the European Economic Area (EEA).

PSMA-PET imaging represents a significant advance in prostate cancer management, largely replacing conventional imaging methods such as bone scans and computed tomography (CT) scans as the standard of care after initial diagnosis and biochemical recurrence (BCR) in the United States. Global guidelines recognize its superior accuracy in staging primary disease and assessing BCR<sup>15</sup>.

## About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix® (kit for the preparation of gallium-68 (<sup>68</sup>Ga) gozetotide injection), Telix's first generation PSMA-PET imaging agent, has been approved in multiple markets globally.

Visit [www.telixpharma.com](http://www.telixpharma.com) for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

## Telix Investor Relations (Global)

Ms. Kyahn Williamson  
Telix Pharmaceuticals Limited  
SVP Investor Relations and Corporate Communications  
Email: [kyahn.williamson@telixpharma.com](mailto:kyahn.williamson@telixpharma.com)

## Telix Investor Relations (U.S.)

Annie Kasparian  
Telix Pharmaceuticals Limited  
Director Investor Relations and Corporate Communications  
Email: [annie.kasparian@telixpharma.com](mailto:annie.kasparian@telixpharma.com)

## Media Contact

Eliza Schleifstein  
917.763.8106 (Mobile)  
Eliza@schleifsteinpr.com

<sup>9</sup> Goetz Partners research 2020.

<sup>10</sup> Telix ASX disclosure 20 December 2021.

<sup>11</sup> Telix ASX disclosure 2 November 2021.

<sup>12</sup> Telix ASX disclosure 14 October 2022.

<sup>13</sup> Telix ASX disclosure 18 March 2025.

<sup>14</sup> Telix ASX disclosure 13 February 2025.

Legal Notices

*Cautionary Statement Regarding Forward-Looking Statements.*

*You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.*

*The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.*

*This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.*

*Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.*

©2026 Telix Pharmaceuticals Limited. All rights reserved.

<sup>15</sup> NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.3.2026; EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid 2025. ISBN 978-94-92671-29-5: <https://uroweb.org/guidelines/prostate-cancer>; Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2023: <https://www.esmo.org/guidelines/guidelines-by-topic/esmo-clinical-practice-guidelines-genitourinary-cancers/clinical-practice-guidelines-prostate-cancer/eupdate-prostate-cancer-treatment-recommendations>

